Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Print: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i2.20
pages 145-159

Src Kinase Inhibitors: Promising Cancer Therapeutics?

Helen Creedon
Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh
Valerie G . Brunton
Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh


Src is the cellular counterpart of the first identified viral oncogene v-Src. It forms part of a large family of nonreceptor tyrosine kinases that have been extensively studied over the last few decades. This has led to the realization that Src can regulate a number of signaling pathways that impact on the behavior of tumor cells, including proliferation, survival, migration, invasion, and angiogenesis. There are currently four Src inhibitors (dasatinib, saracatinib, bosutinib, and KX01) in clinical development, and although there is a plethora of information on their activity in preclinical models their clinical efficacy has been disappointing. Here we review the current status of the Src inhibitors and highlight the difficulties involved in assessing these therapeutics in the clinical setting. In the future it will be important to combine our knowledge of basic Src biology with the use of appropriate preclinical models to aid the design of clinical trials. Taking this integrated approach will hopefully help to realize the true potential of Src kinase inhibitors.

Articles with similar content:

Multiple Defects of Natural Killer Cells in Cancer Patients: Anarchy, Dysregulated Systemic Immunity, and Immunosuppression in Metastatic Cancer
Critical Reviews™ in Immunology, Vol.40, 2020, issue 2
Tamara Lah Turnsek, Barbara Breznik, Meng-Wei Ko, Kristin Y. Nguyen, Janko Kos, Kawaljit Kaur, Anahid Jewett, Paul Wong, Emanuela Senjor
Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Vinod Prabhu, Venugopal Vinod Prabhu
Targeting Integrins in Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Chiara Pazzagli, Sandra Donnini
Altered Expression of Histone Deacetylases in Cancer
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Carmen Jeronimo, Rui Manuel Ferreira Henrique, Diana Montezuma
The Multilayered Regulation of the Oncogenic Protein YY1
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Raed Rizkallah, Myra M. Hurt